Cytotoxic Organometallic Iridium(III) Complexes
Iridium complexes attract a lot of attention as highly promising antitumor agents due to their various structures, which offer the modification of their physicochemical and biological effects. Compared to conventional platinum-based drugs, iridium complexes are commonly thought to be more active in...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-02-01
|
| Series: | Molecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1420-3049/30/4/801 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849719457933426688 |
|---|---|
| author | Irena Kostova |
| author_facet | Irena Kostova |
| author_sort | Irena Kostova |
| collection | DOAJ |
| description | Iridium complexes attract a lot of attention as highly promising antitumor agents due to their various structures, which offer the modification of their physicochemical and biological effects. Compared to conventional platinum-based drugs, iridium complexes are commonly thought to be more active in tumors, resistant to platinum agents and more stable in air and moisture conditions. Chloridoiridium complexes offer a range of advantages facilitating their rational design, reactivity and photochemical activity, leading to different cytotoxic profiles, diverse mechanisms of action and specific intracellular organelles as targets. They are also known as good light-mediated chemotherapeutics, serving as bioimaging and biosensing agents. The potential biological and photophysical properties of chloridoiridium(III) complexes can be readily controlled by suitable ligand modifications and substitution patterns, providing a wide range of versatile structures. Over the years, numerous different structural types of chloridoiridium complexes have been developed and studied for their antineoplastic activity. In this review, the recent advances in the cytotoxicity studies of chloridoiridium(III) compounds have been summarized. The studied complexes have been categorized in this review according to the number of coordinated ligands, the type of donor atoms, nuclearity of the complexes, etc., allowing for a thorough discussion of the structure–activity relationship. |
| format | Article |
| id | doaj-art-bb5de1d783464645af753708be9ddc4d |
| institution | DOAJ |
| issn | 1420-3049 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Molecules |
| spelling | doaj-art-bb5de1d783464645af753708be9ddc4d2025-08-20T03:12:09ZengMDPI AGMolecules1420-30492025-02-0130480110.3390/molecules30040801Cytotoxic Organometallic Iridium(III) ComplexesIrena Kostova0Department of Chemistry, Faculty of Pharmacy, Medical University-Sofia, 1000 Sofia, BulgariaIridium complexes attract a lot of attention as highly promising antitumor agents due to their various structures, which offer the modification of their physicochemical and biological effects. Compared to conventional platinum-based drugs, iridium complexes are commonly thought to be more active in tumors, resistant to platinum agents and more stable in air and moisture conditions. Chloridoiridium complexes offer a range of advantages facilitating their rational design, reactivity and photochemical activity, leading to different cytotoxic profiles, diverse mechanisms of action and specific intracellular organelles as targets. They are also known as good light-mediated chemotherapeutics, serving as bioimaging and biosensing agents. The potential biological and photophysical properties of chloridoiridium(III) complexes can be readily controlled by suitable ligand modifications and substitution patterns, providing a wide range of versatile structures. Over the years, numerous different structural types of chloridoiridium complexes have been developed and studied for their antineoplastic activity. In this review, the recent advances in the cytotoxicity studies of chloridoiridium(III) compounds have been summarized. The studied complexes have been categorized in this review according to the number of coordinated ligands, the type of donor atoms, nuclearity of the complexes, etc., allowing for a thorough discussion of the structure–activity relationship.https://www.mdpi.com/1420-3049/30/4/801chloridoiridium(III)complexesanticancercytotoxicreview |
| spellingShingle | Irena Kostova Cytotoxic Organometallic Iridium(III) Complexes Molecules chloridoiridium(III) complexes anticancer cytotoxic review |
| title | Cytotoxic Organometallic Iridium(III) Complexes |
| title_full | Cytotoxic Organometallic Iridium(III) Complexes |
| title_fullStr | Cytotoxic Organometallic Iridium(III) Complexes |
| title_full_unstemmed | Cytotoxic Organometallic Iridium(III) Complexes |
| title_short | Cytotoxic Organometallic Iridium(III) Complexes |
| title_sort | cytotoxic organometallic iridium iii complexes |
| topic | chloridoiridium(III) complexes anticancer cytotoxic review |
| url | https://www.mdpi.com/1420-3049/30/4/801 |
| work_keys_str_mv | AT irenakostova cytotoxicorganometalliciridiumiiicomplexes |